Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, and I'm not implying they'll have to drop the price a whole lot, just that their buyers may want them to give a little since the price tanked with the announcement. Have they published the underwriter's discount yet?
no, it's set, $2.30 some buyers already shorted +15% last night.
If there isn't enough buyers, the market makers listed in the press release, will pump up the price a few cents for the next 30 days.
They can't exactly expect a premium to the market price for an offering, and may have to adjust it one more time before the offering closes.
...and TRVN isn't saddled with civil litigation (to the tune of multiples of $$billions) for essentially white-collar drug-dealing.
I’ll tell you what’s special. It doesn’t have the same sleepy effect as morphine which translates to everything. Patients can get up, move around and decrease risk of clots and bed soars plus will contribute to earlier discharge saving hospitals millions. Added effect patients will be able to have bowel movements faster which will decrease pain as well as the complications that come with that problem. I know I deal with this everyday as a healthcare worker!
I’ll tell you what’s special. It doesn’t have the same sleepy effect as morphine which translates to everything. Patients can get up, move around and decrease risk of clots and bed soars plus will contribute to earlier discharge saving hospitals millions. Added effect patients will be able to have bowel movements faster which will decrease pain as well as the complications that come with that problem. I know I deal with this everyday as a healthcare worker!
This is all a temporary set back in pps.
$2.3 worse than I thought
Trevena Announces Pricing of $50 Million Public Offering of Common Stock
9:27 am ET August 12, 2020 (Globe Newswire) Print
Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system ("CNS") disorders, announced today the pricing of its previously announced underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $2.30 per share. Trevena has also granted the underwriters a 30-day option to purchase up to 3,260,869 additional shares of common stock, at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering are expected to be approximately $50 million, before deducting the underwriting discounts and commissions and other offering expenses. The closing of the offering is expected to occur on or about August 14, 2020, subject to the satisfaction of customary closing conditions.
Guggenheim Securities, LLC is acting as lead book-running manager for the offering. Cantor Fitzgerald & Co. is also acting as book-running manager for the offering. JMP Securities LLC and Oppenheimer & Co. Inc. are acting as co-lead managers for the offering. H.C. Wainwright & Co., LLC is also acting as co-manager for the offering.
Trevena intends to use the net proceeds from the offering primarily to fund the commercialization of OLINVYK, to support the clinical development of its pipelines assets and for working capital and general corporate purposes.
TRVN Kool aid keeps getting stronger - may as well get the sheep drunk and high before the fleecing. Predict a lot of "what happened...???" posts once this is back below 1 dollar.
Can anyone tell me what is so special about oliceridine compared to other opiates?
Morphine and other opiates can also be given IV. Looking into it further, it doesn't look like this drug as significantly different from all the other opiated already on the market. Why would any hospital be stupid enough to pay higher for this as opposed to so many cheaper and effective generic alternatives?
My bad for poor DD. All my paper gains down the drain.
Wow!!!! Thanks for that, I really, really appreciate that you doing it. I am truly touched. Thank you very much again. God bless you and your family. Thanks
Send Management an email expressing your indignation.
I did earlier. Not that anything will come of it.
Get In Touch With Us
Address
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
Phone Tel: (610) 354-8840
Email: ir@trevena.com
Wow this week just keeps getting worse and worse for you...
This did not hit your $100 target?
So many buys...so many losers...
Let me know when Kodk hits $300 btw lol...
Or was that $3.?
Hahaha...
And then... an offering... classic.
This company pulled a fast one today after hours, I lost a chit ton, to the tune of 40 grand on this deal because of the offering announcement. I bought yesterday in the 3's heavily and I bought the other half today to average down, but this was worse trade this year by far, yes I have lost before but this was absolutely the worse timing to do an offering right after the company said during the conference call yesterday that they had the funds to continue operations well into 2021 and yet they pulled this stunt. They are very dirty, very.
Uncertainty about the offering didn’t help the share price. It will recover.
Uh oh, lol.
We’ve got a winner here. Not too many worries or arrests looming that I can find. Good luck!
$2.31 at 6:30pm
Change Since Close
-0.43 (-15.69%)
probably priced 2.32 to 2.35
Without any details it is impossible to say. Why they would make the
announcement without providing the substance is beyond me. Perhaps
TRVN wants to raise money to hire its own sales force...that may be
better than a JV because it keeps them open to an eventual BO. I really
do not think any small biopharma should ever "go it alone" once they have
a viable product. Normally, the company will either JV or sell the company. Even if the company says they will hire a sales force it does
not preclude an acquirer if the right deal is brought to the table.
"If" TRVN really does have a potential $1 billion plus product...the
BO value should be a multiple of that (usually 4-5 X peak revenues.)
TRVN has a market cap of under $300 million...so if the share price
wrong? Or is the market saying that the company can't achieve such
a lofty sales goal...even with a BP acquirer. I wish I knew.
This could be a $10 plus share price within a year is decent sales
materialize. (I would rather a BO emerges instead.)
Does this help or hurt the stock?
* * $TRVN Video Chart 08-11-2020 * *
Link to Video - click here to watch the technical chart video
No details have been disclosed yet...kind of strange.
whats the PO price going to be though
Explains the recent stock action...NOW, the smart money buys!
Trevena Announces Proposed Public Offering of Common Stock
4:01 pm ET August 11, 2020 (Globe Newswire) Print
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system ("CNS") disorders, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Trevena intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Guggenheim Securities, LLC is acting as lead book-running manager for the offering. Cantor Fitzgerald & Co. is also acting as a book-running manager for the offering.
The securities described above are being offered by Trevena pursuant to a registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email atGSEquityProspectusDelivery@guggenheimpartners.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC atwww.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
My girl from aryc! We surf same waves!
Right, and don't forget the deal they already have with China where they are set to receive milestone and royalty payments on sales of Oliceridine. Also, if the current London study on TRVN's TRV047 proves to be an effective treatment for Covid-19 patients whose lungs are in dire need of help and repair, TRVN would be a hero and the share price would fly to the moon, as they say. lol.
Eventually, the market will catch on. It's always fun to be early to the party.
Found this to confirm London study:
https://wwwf.imperial.ac.uk/blog/dobs-staff/2020/07/14/funding-successes-july-2020/
I would have to agree with that Dino
Yes stair step set up is best way to make good trades. Parabolic moves always fall very hard.
8/11/2020 HC Wainwright Boost Price Target Buy $4.00 to $5.00
If the drug will be ready for sales in 90 days that will bring in revenues "The drugmaker said Olinvyk will be available in about 90 days."
Looking ahead, Trevena said it has enough funds to operate through the end of 2021, including the commercialization of Olinvyk.
good to see Analyst raise target from 4$ to 5$
no gaps on the chart so it looks like a solid move
Well I bought a good amount of shares today on the selloff. Way to many paid up pre market yesterday went up way to far and fast. Now I would like to see us go up slow and steady now that all the flipper has sold out. good luck this might turn into a good winner mid term.
Added another 8000 shares today. This is going to run when given time.
Clay has it correct most of time
if you take time to watch them you’ll learn something
All numbers game and a little luck
make money not Sleepless nights
FDA Approval and decent quarterly report yet it's going down. I don't get it. Does anyone have a clue?
This POS will never trade above 4 again....ever
TRVN stock was trading early pre-market yesterday on news 4.55.it will go back to that price
Stair step setup is the best way, I got a reasonable amount of shares, every time it dips I will buy again, this is going through 10-12 dollars by September/October. The news was awesome and so was the conference call, but you need to remember there a lot of people bag holding since sub $1.00 it was normal for them to take profits off the table, now it has become scalpers, manipulators and shorts controlling this for right now, let them do their job, the best thing you can do if you have enough powder is add on the dip, this company is going to make a lot of people a lot of money in the mid to long term. The drawback on the conference call was, they didn't announce partnership and they are awaiting DEA approval for OLI. This is solid stock and definitely will go easily over 30 dollars if their plans are excepted properly. I personally want to see a buyout of some form of partnership.. Good luck.
The following article may indicate an advantage for TRVN. Pfizer could buy TRVN without any of the liabilities other Opioids manufacturers have to deal with it:
Opioid Scandal Haunts Drug Companies As They Respond To Pandemic
https://www.npr.org/sections/coronavirus-live-updates/2020/08/10/900854967/opioid-scandal-haunts-drug-companies-as-they-respond-to-pandemic
As drug firms race to position themselves as key players in the coronavirus fight, the industry faces a renewed wave of civil lawsuits stemming from its role in the nation's deadly opioid epidemic.
Thousands of cases that ground to a halt because of the COVID-19 pandemic are moving forward again as local, state and federal courts reopen around the United States.
"I think it's quite serious," said Rebecca Haffajee, who studies opioid litigation for the Rand Corp. and the University of Michigan. "There have been delays associated with COVID, but I actually don't think there's an end in sight for a lot of these defendants."
Pressure on the opioid front comes even as drug firms are producing medicines and providing services, including testing and vaccine development, needed to help slow the pandemic.
"These companies are and have argued that they are essential businesses" during the coronavirus crisis, Haffajee noted.
But some of the nation's biggest companies — including CVS, Johnson & Johnson, McKesson and Walgreens — remain mired in legal and financial uncertainty tied to their decades-long manufacture and sale of prescription opioids.
The highly addictive medications have contributed to the overdose deaths of more than 230,000 Americans, according to the Centers for Disease Control and Prevention.
Fallout from the opioid crisis has already forced two companies, Purdue Pharma and Insys Therapeutics, into bankruptcy.
Mallinckrodt, a maker of generic opioids, announced last week it is considering filing for Chapter 11 protection, in part because of opioid liabilities.
Nevertheless, Haffajee said, "the goal is not necessarily to put these pharmacies, these manufacturers and these distributors out of business altogether."
"That would actually be bad for public health and for the health care industry."
Companies look to pivot away from opioid scandal
In addition to financial and legal uncertainty, years of opioid litigation have meant devastating public relations blows for some of the drug industry's highest profile companies as well as their owners.
They were once viewed as philanthropists and champions of public health, but court filings have revealed the role executives played in downplaying the risk of prescription pain medications to boost profits.
Just last year, Oklahoma's attorney general described Johnson & Johnson as a "drug kingpin" for its role pushing medical opioids. A state judge in that case ruled the company must pay $465 million in damages.
In a separate case, the company also agreed to pay two Ohio counties $20.4 million to settle opioid claims.
Johnson & Johnson has denied any wrongdoing in these cases, and now the company appears eager to pivot, recasting itself as a major player in the race for a coronavirus vaccine.
"We're facing arguably one of the most serious health challenges the world has ever faced, but we're doing our absolute very best to make sure we can navigate our way through," CEO Alex Gorsky said in a webcast to investors this summer.
Last week Johnson & Johnson announced a $1 billion deal with the federal government aimed at producing millions of doses of a vaccine now in development.
Pressure grows to reach a settlement
But a series of legal developments in recent weeks complicate the drug industry's efforts to put the opioid scandal behind it.
At the end of July, the Justice Department filed civil and criminal claims against Purdue Pharma, makers of Oxycontin, worth more than $13 billion, according to Reuters, complicating that company's structured bankruptcy proceedings.
Last week, a federal judge in Ohio ruled that a major case against pharmacy chains can go forward. Local governments in that suit claim corner drugstores dispensed huge quantities of opioids without proper safeguards against diversion and misuse.
Meanwhile, a court in Tennessee scheduled a jury trial for next month involving drug-makers Endo and Mallinckrodt. Local governments in that case are seeking opioid-related damages of roughly $2.5 billion.
"They're going to have to answer for what they've done," said Gerard Stranch, an attorney representing Tennessee communities ravaged by the addiction crisis.
As civil and criminal cases move forward, pressure is growing to reach a national settlement of opioid-related cases similar to the Big Tobacco payouts of the 1990s.
The goal is to cap the drug industry's total liability and end financial instability for firms while accelerating payouts to cash-strapped communities.
Several proposed settlements unveiled last year, involving Johnson & Johnson, Teva and others, still haven't been finalized.
Stranch predicted companies would need to increase their offers of compensation before local governments agree to cut deals.
"They're not going to be allowed to just walk away and say, well, a couple hundred million dollars is the best we can do," he said.
But even the drug industry's fiercest critics also acknowledged firms lack the cash to compensate Americans harmed by prescription opioids and the addiction crisis fully. By some estimates, the opioid crisis is costing communities hundreds of billions of dollars a year.
"Even if you took all their money, you're not going to be able to right the harm they've done," Stranch said. "The amount of damage is simply too great."
In reality - for a drug approval from FDA, market reaction is very muted. Not much gain. I hope someone buys us else the approval will go wasted
TRVN I like this one & i like it ALOT
News: $TRVN Why Trevena Stock Surged Today
Shares of Trevena (NASDAQ: TRVN) soared 31.5% on Monday after the biopharmaceutical company announced regulatory approval of its new pain-management treatment. Trevena said the U.S. Food and Drug Administration (FDA) approved its new opioid agonist, called Olinvyk, for the mana...
In case you are interested TRVN - Why Trevena Stock Surged Today
TRVN chart forming another bullish pattern here imo.
News: $TRVN 3 Top Biotech Stocks To Watch This Week, 2 Making Big Moves
Are These Biotech Stocks On Your Watchlist? Are you constantly searching for small-cap stocks ? Like it or not, small-cap stocks have been a popular asset class due to lower entry barriers and investors are drawn to the space due to their potentially massive breakouts. This year, the small-c...
Find out more TRVN - 3 Top Biotech Stocks To Watch This Week, 2 Making Big Moves
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1319
|
Created
|
06/29/14
|
Type
|
Free
|
Moderators |
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders.
The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.
Trevena is guided by an innovative spirit and an unwavering commitment to patients. It is a place driven by its employees – passionate and talented industry experts who operate with integrity, transparency, and respect for one another. Trevena employees are united in one mission: to deliver new medicines that address critical areas of need in CNS disorders.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |